Uncover the truth about GLP-1 weight loss drugs like Ozempic and Mounjaro. Learn how they work, who benefits most, potential risks, and why experts say they can be game-changing tools for fighting ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP ...

Republican leaders pushed back on the DHHS approach. They also tied the dispute to broader state budget negotiations.

Ozempic and drugs like it have done wonders for weight loss by mimicking the natural hormone GLP-1 ( glucagon-like peptide-1 ...

You've likely heard about glucagon-like peptide-1 agonists – usually referred to as GLP-1 medications, and more wildly ...

In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by the National Center for ...